Rinvoq’s year-over-year sales growth decelerated to 20.2% from 28.6%, contrasting with Skyrizi’s accelerating 29.2% expansion.
AbbVie’s Rinvoq posted a 20.2% year-over-year sales increase in the latest quarter, down from 28.6% growth in the prior period. The slowdown contrasts with Skyrizi, which accelerated to 29.2% growth, reinforcing its role as a key revenue driver post-Humira.
The company’s transition from Humira has been successful, with both drugs now anchoring its growth strategy. However, Rinvoq’s deceleration, while still robust for a multi-billion-dollar product, introduces a potential risk to AbbVie’s dual-pillar investment thesis.
AbbVie shares remain near record highs, reflecting confidence in its pipeline. Analysts note that a single quarter’s shift may not signal a trend, but the magnitude of the slowdown warrants closer scrutiny from investors.